Medicenna Therapeutics Corp.

TSX:MDNA Stock Report

Market Cap: CA$133.7m

Medicenna Therapeutics Management

Management criteria checks 1/4

Medicenna Therapeutics' CEO is Fahar Merchant, appointed in Oct 2011, has a tenure of 13.17 years. total yearly compensation is CA$1.03M, comprised of 50.3% salary and 49.7% bonuses, including company stock and options. directly owns 7.37% of the company’s shares, worth CA$9.85M. The average tenure of the management team and the board of directors is 10.3 years and 2.9 years respectively.

Key information

Fahar Merchant

Chief executive officer

CA$1.0m

Total compensation

CEO salary percentage50.3%
CEO tenure13.2yrs
CEO ownership7.4%
Management average tenure10.3yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18
We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14
Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28
Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08
Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01
Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely

Aug 07
We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely

Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?

Apr 14
Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?

We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely

Dec 30
We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Fahar Merchant's remuneration changed compared to Medicenna Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$27m

Jun 30 2024n/an/a

-CA$26m

Mar 31 2024CA$1mCA$519k

-CA$25m

Dec 31 2023n/an/a

-CA$15m

Sep 30 2023n/an/a

-CA$12m

Jun 30 2023n/an/a

-CA$9m

Mar 31 2023CA$877kCA$428k

-CA$10m

Dec 31 2022n/an/a

-CA$9m

Sep 30 2022n/an/a

-CA$13m

Jun 30 2022n/an/a

-CA$20m

Mar 31 2022CA$894kCA$436k

-CA$23m

Dec 31 2021n/an/a

-CA$25m

Sep 30 2021n/an/a

-CA$26m

Jun 30 2021n/an/a

-CA$21m

Mar 31 2021CA$868kCA$543k

-CA$17m

Dec 31 2020n/an/a

-CA$14m

Sep 30 2020n/an/a

-CA$11m

Jun 30 2020n/an/a

-CA$9m

Mar 31 2020CA$852kCA$411k

-CA$8m

Dec 31 2019n/an/a

-CA$7m

Sep 30 2019n/an/a

-CA$6m

Jun 30 2019n/an/a

-CA$5m

Mar 31 2019CA$565kCA$375k

-CA$5m

Dec 31 2018n/an/a

-CA$5m

Sep 30 2018n/an/a

-CA$5m

Jun 30 2018n/an/a

-CA$6m

Mar 31 2018CA$907kCA$380k

-CA$7m

Compensation vs Market: Fahar's total compensation ($USD717.38K) is above average for companies of similar size in the Canadian market ($USD164.16K).

Compensation vs Earnings: Fahar's compensation has increased whilst the company is unprofitable.

CEO

Fahar Merchant (67 yo)

13.2yrs

Tenure

CA$1,030,905

Compensation

Dr. Fahar Merchant, Ph.D. serves as the Chairman, Chief Executive Officer and President at A2 Acquisition Corp. Dr. Merchant has been President and Chief Executive Officer and Director of Medicenna Therape...

Leadership Team

NamePositionTenureCompensationOwnership
Fahar Merchant
Founder13.2yrsCA$1.03m7.37%
CA$ 9.9m
Rosemina Merchant
Founder & Chief Development Officer13.7yrsCA$705.93k7.16%
CA$ 9.6m
David Hyman
Chief Financial Officerless than a yearCA$165.09k0.026%
CA$ 34.2k
Samuel Denmeade
Scientific Advisorno datano datano data

10.3yrs

Average Tenure

67yo

Average Age

Experienced Management: MDNA's management team is seasoned and experienced (10.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Fahar Merchant
Founder13.2yrsCA$1.03m7.37%
CA$ 9.9m
John Geltosky
Independent Director4.3yrsCA$96.70kno data
Karen Dawes
Independent Director5.3yrsCA$96.70k0.058%
CA$ 77.3k
Albert Beraldo
Lead Independent Director8.1yrsCA$129.20k0.42%
CA$ 555.7k
Lillian Siu
Member of Clinical Advisory Board2.8yrsno datano data
David Mooney
Member of Scientific Advisory Board2.9yrsno datano data
John Sampson
Independent Director3.3yrsCA$86.70kno data
Sergio Quezada
Chairman of Scientific Advisory Board2.9yrsno datano data
Paolo Ascierto
Member of Clinical Advisory Board2.8yrsno datano data
Burkhard Becher
Member of Scientific Advisory Board2.9yrsno datano data
William Redmond
Member of Scientific Advisory Board2.9yrsno datano data
Hussein Tawbi
Member of Clinical Advisory Board2.8yrsno datano data

2.9yrs

Average Tenure

69yo

Average Age

Experienced Board: MDNA's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medicenna Therapeutics Corp. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles ZhuGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.
Catherine NovackJonesTrading Institutional Services, LLC